NORSE‑ICM Project
Paris Brain Institute – Pitié‑Salpêtrière Hospital (Paris)
A research initiative to advance the understanding, diagnosis, and treatment of New Onset Refractory Status Epilepticus (NORSE) and its subtype FIRES.
What's new
Latest news
Training School · Fall 2027 · Paris
Neuroinflammation & Epilepsy
From Mechanisms to Precision Immunotherapy
International Training School and Translational Workshop — 2.5 days at the Paris Brain Institute.
Longitudinal serum and CSF cytokine dynamics in NORSE: associations with immunotherapy exposure
Hanin A, Marois C, Cosme L, et al.
Read the article↗
Exploring pathways leading to drug-resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus
Hanin A, Marois C, Guillemaud M, et al.
Read the article↗
About the project
Who we are
NORSE is a rare and poorly understood medical emergency. The ICM NORSE team is developing an innovative approach to better diagnose, understand, and treat this condition.
The team
The ICM NORSE team is led by Pr. Vincent Navarro and Dr. Aurélie Hanin, within the EPIC research team (Clinical and Experimental Epilepsy, led by Pr. Navarro and Pr. Poncer) at the Paris Brain Institute (ICM). Based at the Pitié‑Salpêtrière Hospital, we combine clinical expertise and fundamental research to advance the field.
Our mission
We focus on de novo refractory status epilepticus, occurring in patients without any prior neurological disease or epilepsy, and without any acute or active structural, toxic, or metabolic cause identified in the first few days (see definitions).
Reference: Hirsch et al., Epilepsia 2018
Definitions
NORSE
New Onset Refractory Status Epilepticus
A clinical presentation in a patient without prior history of epilepsy or another relevant neurological disorder, where a refractory status epilepticus occurs without a clearly identifiable acute structural, toxic, metabolic or infectious cause within the first days of evaluation.
PMID 29399791 →FIRES
Febrile Infection-Related Epilepsy Syndrome
A subcategory of NORSE that requires a febrile infection between 2 weeks and 24 hours before the onset of refractory status epilepticus, with or without fever at the onset of status epilepticus, and excluding patients with diagnosed encephalitis.
PMID 29399791 →What we do
Our objectives
Characterize
Immune-mediated processes and brain injury in NORSE.
Integrate
Clinical data, neuroimaging, and biological analyses.
Deliver
Personalized medicine based on individual patient data.
Resources
Explore the platform
The people behind the project
Our team
The NORSE‑ICM Team
Paris Brain Institute — Pitié‑Salpêtrière Hospital
Pr. Vincent Navarro
MD, PhD
Neurologist — Team Leader
Dr. Aurélie Hanin
PharmD, PhD
Research Coordinator & Biologist
Dr. Zineb Hayatou
Clinical Research
Associate (CRA)
Léa Cosme
Project
Manager (PM)
Matthew Gruen
Data
Analyst
For clinicians & researchers
Need a cytokine analysis?
Our cytokine platform measures inflammatory markers in biological samples. If you would like a cytokine analysis for a patient with NORSE or FIRES, or for a research project, feel free to contact us.
- 1
Contact us
Send us a short email describing your request.
- 2
Describe your samples
Sample type (serum, plasma, CSF), number of samples and context. No identifying data.
- 3
We get back to you
A member of the team will contact you to discuss feasibility and logistics.
Opens a pre-filled email to aurelie.hanin@icm-institute.org.
Get in touch
Contact us
For any inquiries regarding the NORSE‑ICM project or collaborations: